Literature DB >> 18712275

Development of a self-reporting questionnaire, BURMIG, to evaluate the burden of migraine.

Colette Andrée1, Michel Vaillant, Christelle Rott, Zaza Katsarava, Peter S Sándor.   

Abstract

We developed a 77-item self-reporting questionnaire to assess the burden of migraine (BURMIG), including headache characteristics, migraine associated disability, comorbidities, management, and the consequences on the patients' lives. We translated BURMIG into four languages (French, Portuguese, German and English) and tested it in 130 headache patients (20 pain clinic, 17 primary care and 93 general public) in Luxembourg. We performed a linguistic and a face-content validation and tested the questionnaire for its comprehensiveness, internal consistency and for its retest-reliability at an interval of 1 month (completion rates were 79.6 and 76.4%, for test and retest, respectively). Retest-reliability for the different parts of the questionnaire varied between 0.6 and 1.0 (Kappa coefficient), with an intracorrelation coefficient of 0.7-1.0. The internal consistency was between 0.74 and 0.91 (Cronbach's alpha). The questionnaire BURMIG is suitable to evaluate the burden of migraine and can be used in English, German, French and Portuguese.

Entities:  

Mesh:

Year:  2008        PMID: 18712275      PMCID: PMC3452196          DOI: 10.1007/s10194-008-0059-1

Source DB:  PubMed          Journal:  J Headache Pain        ISSN: 1129-2369            Impact factor:   7.277


  15 in total

Review 1.  Migraine--current understanding and treatment.

Authors:  Peter J Goadsby; Richard B Lipton; Michel D Ferrari
Journal:  N Engl J Med       Date:  2002-01-24       Impact factor: 91.245

2.  Migraine diagnosis and treatment: results from the American Migraine Study II.

Authors:  R B Lipton; S Diamond; M Reed; M L Diamond; W F Stewart
Journal:  Headache       Date:  2001 Jul-Aug       Impact factor: 5.887

3.  The PHQ-9: validity of a brief depression severity measure.

Authors:  K Kroenke; R L Spitzer; J B Williams
Journal:  J Gen Intern Med       Date:  2001-09       Impact factor: 5.128

4.  Epidemiology and socio-economic impact of headache.

Authors:  B K Rasmussen
Journal:  Cephalalgia       Date:  1999-12       Impact factor: 6.292

5.  A self-administered screener for migraine in primary care: The ID Migraine validation study.

Authors:  R B Lipton; D Dodick; R Sadovsky; K Kolodner; J Endicott; J Hettiarachchi; W Harrison
Journal:  Neurology       Date:  2003-08-12       Impact factor: 9.910

6.  Impact of migraine and tension-type headache on life-style, consulting behaviour, and medication use: a Canadian population survey.

Authors:  J Edmeads; H Findlay; P Tugwell; W Pryse-Phillips; R F Nelson; T J Murray
Journal:  Can J Neurol Sci       Date:  1993-05       Impact factor: 2.104

7.  North Staffordshire Headache Survey: development, reliability and validity of a questionnaire for use in a general population survey.

Authors:  H F Boardman; E Thomas; D S Millson; E A MacGregor; W F Laughey; P R Croft
Journal:  Cephalalgia       Date:  2003-06       Impact factor: 6.292

8.  Impact of migraine in the United States: data from the National Health Interview Survey.

Authors:  P E Stang; J T Osterhaus
Journal:  Headache       Date:  1993-01       Impact factor: 5.887

9.  A study of migraine and its effects in a working population.

Authors:  A H Mounstephen; R K Harrison
Journal:  Occup Med (Lond)       Date:  1995-12       Impact factor: 1.611

10.  The family impact of migraine: population-based studies in the USA and UK.

Authors:  R B Lipton; M E Bigal; K Kolodner; W F Stewart; J N Liberman; T J Steiner
Journal:  Cephalalgia       Date:  2003-07       Impact factor: 6.292

View more
  1 in total

1.  The Eurolight project: the impact of primary headache disorders in Europe. Description of methods.

Authors:  C Andrée; L J Stovner; T J Steiner; J Barré; Z Katsarava; J M Lainez; M Lanteri-Minet; G Mick; D Rastenyte; E Ruiz de la Torre; C Tassorelli; P Vriezen; C Lampl
Journal:  J Headache Pain       Date:  2011-06-10       Impact factor: 7.277

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.